Introduction
The neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease, are a group of fatal, inherited neurodegenerative lysosomal storage diseases (LSDs). They are characterised by the progressive accumulation of autofluorescent storage material in the lysosome. Clinical symptoms of NCL usually present in childhood and include loss of vision, seizures, cognitive decline and mental deterioration ultimately resulting in premature death (1) . The combined incidence of NCL varies across different countries from 1:12,500 to 1:100,000 (2) . At least 13 genes are linked to the development of the disease, five of which encode transmembrane proteins that reside in the membrane of the lysosome, endoplasmic reticulum (ER) or ER-Golgi intermedi-ate compartment (3) . There is no licensed therapy available for NCLs caused by transmembrane protein deficiencies and only palliative care is offered to patients. CLN6 disease is a form of NCL caused by mutations in the gene CLN6 encoding a transmembrane, endoplasmic reticulum (ER) protein of unknown function (4) . Disease symptoms usually present in children between 1.5 to 8 years of age and include loss of vision, ataxia, motor delay, seizures and cognitive abnormalities. Childhood CLN6 disease progresses rapidly leading to premature death between 5 to 12 years of age (5) . Mutations in CLN6 can also lead to a rare adult-onset form of NCL, referred to as Kufs disease. The main differences between the two conditions are the latter age of onset and a lack of visual involvement in adult patients (6) . The Cln6 nclf mouse is a naturally occurring model of CLN6 disease. Cln6 nclf mice carry a 1-bp insertion mutation in the gene Cln6. It is analogous to a common mutation found in CLN6 patients of Pakistani origin that results in a premature stop codon and a truncated protein product (7, 8) . Cln6deficient mice recapitulate the human disease with severe retinal and neuronal degeneration. The disease phenotype involves blindness, progressive loss of locomotor function and motor coordination, and a reduced mean survival of approximately 12 months of age, rendering it a useful animal model to study therapeutic interventions for CLN6 disease (9) . Adeno-associated virus (AAV)-mediated gene therapies are proving to be effective for the treatment of a wide range of inherited disorders (10) (11) (12) (13) (14) . However, the development of gene therapies for conditions that affect multiple regions of the brain appears to be more challenging due to its large size, complex anatomy and the presence of the blood brain barrier (BBB). For this reason, AAV-mediated gene therapy clinical trials for neurodegenerative LSDs have mostly focused on conditions involving genes encoding soluble enzymes including a safety phase I clinical trial for late-infantile onset CLN2 disease (NCT00151216) (15) . Therapies for these diseases are aided by lysosomal cross-correction allowing therapeutic enzymes to be secreted and passed on to surrounding cells via the mannose-6-phosphate pathway (16) . To achieve meaningful therapeutic effects for transmembrane protein de-ficiencies is more challenging as cross-correction does not occur, confining benefit to only those cells that received the vector (17, 18) . A phase I/II clinical trial involving intrathecal delivery of a self-complementary (sc) AAV9.Cb.CLN6 to children suffering from CLN6 disease has been initiated recently (NCT02725580). However, no pre-clinical or clinical data has been published to date demonstrating that CNS-directed gene therapy is beneficial in CLN6 disease. Previously, we have demonstrated that AAV gene supplementation therapy can be used to treat the ocular phenotype in Cln6 nclf mice (19) . Here, we report the successful development of an AAV-mediated gene therapy directly targeting the brain of new-born, presymptomatic Cln6 nclf mice. We establish that neonatal bilateral intracerebroventricular (ICV) injections with an AAV9 vector carrying human CLN6 extend lifespan by more than 90%, attenuate motor skill and coordination deficits, and reduce the neuropathological hallmarks evident in mutant mice. Our work demonstrates the long-term therapeutic effects of AAV-mediated gene therapy in a model of CLN6 disease, and supports the development of CNS-directed gene therapies for CLN6 disease and other forms of NCL caused by transmembrane protein deficiencies.
Results
Bilateral ICV delivery of AAV9.CMV.hCLN6 leads to a widespread expression of CLN6 throughout the brains of wild type mice. Previously, mRNA expression analyses showed Cln6 expression in wild type mouse brains across various regions including cerebellum, hypothalamus, mid brain, cortex (frontal, posterior and entorhinal), hippocampus, thalamus and striatum. Expression was detected from embryonic day (E) 18 with significantly lower Cln6 mRNA levels in Cln6 nclf mutant brains than in wild type brains (20) . Based on these data, we performed bilateral ICV injections in wild type P0-P1 mice (under 24h of age) with a single stranded AAV9 vector carrying human CLN6 (hCLN6) under the control of the CMV promoter (AAV9.CMV.hCLN6). A low dose of 5x10 10 viral genomes (vg) (n = 3) or a high dose of 5x10 11 vg (n = 3) were administered per pup. Noninjected littermates were used as age-matched controls (n = 3). Four weeks post administration, the mouse brains were harvested, fixed and cryo-sectioned along the coronal axis to investigate the biodistribution and transduction efficiency. Immunostaining for human CLN6 4 revealed an extensive rostrocaudal CLN6 expression throughout the brain following injections with the high dose of the vector. Representative images are shown from the cortex (somatosensory cortex barrel field), striatum (caudate nucleus), hippocampus (CA2-3), thalamus (ventral posterolateral and postermedial nuclei), cerebellum (central lobe) and brainstem (gigantocellular nucleus). While administration of the low dose also led to widespread CLN6 expression, anti-CLN6 staining was weaker and regions of the brains were only sparsely transduced (e.g. cortex, cerebellum) ( Figure 1 ). Higher magnification light microscopy of discrete regions of the brain sections revealed CLN6 staining in cells with both neuronal and glial morphology.
To assess for any astroglial-or microglial-mediated inflammatory responses associated with overexpression of human CLN6 in wild type mice, immunostaining with antibodies against the glial fibrillary acidic protein (GFAP) and CD68 was performed. An examination of brain sections stained for GFAP revealed no differences in astrocyte cell morphology and no increase in GFAP staining was observed in brains that received low dose vector compared with age-matched uninjected controls ( Figure S1A, B ). However, a subtle, confined but not significant up-regulation of GFAP staining was observed in the somatosensory barrel cortex region (S1BF) (Figure S1B, S3A). No increase in GFAP staining was detected in any other discrete region examined ( Figure S1A , B). CD68 immunostaining did not reveal any obvious microgliamediated inflammatory responses in wild type brains treated with the high or low dose compared with uninjected brains ( Figure S2A -B, S3B).
Brain-directed gene therapy normalises lifespan and preserves brain weight in Cln6 nclf mice. New-born (P0-P1) Cln6 nclf mice received bilateral ICV injections with AAV9.CMV.hCLN6 at 5x10 11 vg (n = 6) and a small cohort of mutant mice received injections with a lower dose of 1x10 11 vg (n = 2). Age-matched uninjected mutant mice (n = 14) and wild type mice were used as controls (n = 8). As mutant mice do not show a significant loss of bodyweight compared with age-matched wild type mice ( Figure S3 ), the humane endpoint for the experiment was defined by either a poor score in the neurological welfare scoring system or a loss of 10-15% in bodyweight. Untreated Cln6 nclf mice had a mean survival of 11.7 ± 0.15 months with a maximum survival of 12 months (Figure 2A ). Mutant mice that received AAV9.CMV.hCLN6 at 5x10 11 vg and 1x10 11 vg had a significantly prolonged survival with a mean of 22.7 ± 0.81 months (p = 0.0002) and 23.3 months (p = 0.0114), respectively. Three mice treated with high dose vector, one mouse treated with low dose vector and five wild type mice did not deteriorate to reach the humane endpoint. These mice were euthanised between 23 and 24 months of age ( Figure  2A, S4C ). An example video of an untreated end-stage mutant and age-matched treated mutant mouse is shown in supplementary video S1.
We measured the whole brain weight of age-matched treated, untreated and wild type mice. At 12 months, untreated mutant mice had significantly lighter brains than wild type animals (0.410 ± 0.01 g vs. 0.511 ± 0.02 g; p < 0.0001). Mutant mice that received bilateral ICV injections with AAV9.CMV.hCLN6 at 5x10 11 vg had higher brain weights at 12 months than untreated age-matched mutants (0.4413 ± 0.03 g; p < 0.05). The brain weight of treated mice examined at 22-23 months was not significantly different compared with 12 months old treated brains (0.454 ± 0.01 g; p < 0.05). The weight of the treated brains was significantly lower than wild type brains at both 12 and 22-23 months (Figure 2B ). ICV treatment improves motor skill and coordination deficits in Cln6 nclf mice. From 7 months of age, Cln6 nclf mice showed a progressive reduction in the latency to fall in an accelerating rotarod test compared with wild type mice (p < 0.01). Following treatment with high dose vector, mutant mice had a significantly better rotarod performance at 7 months compared with age-matched untreated mutant mice (p < 0.01). The performance of treated mutant mice was variable thereafter but remained better up to 12 months (Figure 3A) . Motor skills and coordination were also assessed in a 1-minute foot-fault test. The number of times a limb fell through the grid was counted and the percentage of incorrect steps was calculated. Untreated Cln6-deficient mice made significantly more mistakes (~9% incorrect steps at 9-11 months,~12% incorrect steps at 11.5 months) compared with wild type mice (~6-8% incorrect steps from 9-11.5 months). Treated Cln6 nclf mice made significantly fewer mistakes than untreated mice (~6-7% incorrect steps across all time points) and were comparable with age-matched wild type controls, demonstrating that the treatment normalised the foot-fault phenotype ( Figure 3B ). To further assess motor function and co-ordination we used a vertical pole test. At 8 months, untreated mutants and wild type mice descended the pole without difficulties. From 9 months onwards, mutants struggled to perform the task and at 11.5 and 12 months they were unable to grasp and climb down the pole in a coordinated manner (see supplementary videos S2-S4). Treated mice performed significantly better than untreated animals and no significant differences were detected between treated Cln6 nclf mice and age-matched wild type controls ( Figure 3C ). A 30-second tail suspension test was used to assess the hindleg clasping phenotype of the mice. In line with the pole climbing data, Cln6-deficient mice showed consistently severe hind limb clasping at 11.5 and 12 months of age ( Fig ; wild type controls (n = 8); Cln6 nclf treated with 5x10 11 vg AAV9.CMV.hCLN6, 22.7 ± 0.81 months (n = 6); Cln6 nclf treated 1x10 11 vg AAV9.CMV.hCLN6, 23.3 months (n = 2). Data represented as means ± SEM, compared by Log-rank test (Mantel-Cox) (***p = 0.0002, *p = 0.0114). (B) Mean brain weights: wild type controls at 12 months, 0.511 ± 0.02 g (n = 10) and 22-23 months, 0.5 ± 0.01 g (n = 6); Cln6 nclf untreated, 0.410 ± 0.01 g (n = 20); Cln6 nclf treated with 5x10 11 vg AAV9.CMV.hCLN6 at 12 months, 0.4413 ± 0.03g (n = 12) and 22-23 months, 0.454 ± 0.01 g (n = 6); 22-23 months Cln6 nclf treated with 1x10 11 vg AAV9.CMV.hCLN6, 0.427 ± 0.04 g (n = 2). Data represented as means ± SD, compared by one-way ANOVA (black asterisks) and two-way ANOVA (grey asterisks) and Dunn's multiple comparison test (* p < 0.05, *** p < 0.0001). ure 3D). Scoring of the phenotype by observers masked to each experimental cohort confirmed that clasping was significantly more severe in untreated Cln6 nclf mice ( Figure 3E , p < 0.0001). At this age, treated Cln6 nclf mice had either no clasping phenotype ( Figure 3D ") or a mild clasping phenotype ( Figure 3D "') demonstrating that the treatment was effective ( Figure 3E , p < 0.005).
Finally, we tested the mobility of the mice in an open field activity test ( Figure 3F ). Consistent with a previous report (9) , no significant differences were found in the total distance travelled ( Figure 3G ), speed ( Figure S5A Figure 3F ) and spent less time in the centre than wild type mice ( Figure  3G' ). Linear regression analysis showed that the amount of time spent in the centre of the arena by the untreated animals decreased significantly between 10 and 11.5 months (p = 0.0059), while no significant change over time was detected in the distance travelled or the time spent in the centre by the treated Cln6 nclf mice or the wild type mice ( Figure 3G , 3G'). Interestingly, this experiment did reveal that treated Cln6 nclf mice were overall more active than untreated and wild type mice, as shown by the longer distance travelled ( Figure 3G ) and more time spent in the centre ( Figure 3G' ).
AAV9.CMV.hCLN6 treatment leads to long-term therapeutic benefit. To assess the long-term effects of the treatment, a cohort of mutant mice that received 5x10 11 vg vector (n = 6) were kept beyond 12 months of age and the performance in the 1-minute foot-fault test was tested every month until the end of the study. The quantification of the test showed that treated Cln6 nclf mice performed the task as well as wild type mice up to 23 months of age ( Figure 4A ), although there may be a slight trend towards deterioration of mobility at the later time points. The performance of the mice was also assessed in the tail suspension test. No significant difference in hind limb clasping was detected between 22-23 months old treated mice and age-matched wild type controls (p = 0.417) ( Figure 4B ). In comparison with the performance at 12 months ( Figure 3E ), the average score of treated Cln6 nclf mice and wild type mice decreased by a similar extent over time, indicating that the treatment effect was maintained for almost 2 years following the injections, equivalent to the lifespan of wild type mice. It should be noted however, that the number of animals at the last time points is limited by the natural lifespan of both groups of mice. As a result the study is powered to detect only a greater than 50% difference in mean clasping score based on the current variation.
Brain-directed gene therapy preserves cortical thickness and reduces loss of neurons in
Cln6-deficient mice. The brains of the mice were harvested, cut along the longitudinal fissure and the right hemisphere of each brain was fixed and cryo-sectioned along the coronal axis. To confirm the transgene expression in the brain of treated mice, we stained the brain sections with antibodies against human CLN6 and the neuronal nuclear marker NeuN. We observed sustained widespread expression of CLN6 throughout the cortex, thalamus, hippocampus (CA1 region) and the primary and secondary visual cortex (V1/V2 region) co-localising with a large number of NeuN-positive cells in treated brains at 12 and 22-23 months ( Figure S6A , B). Co-staining with antibodies against GFAP and CD68 identified a small number of astrocytes that were also positive for CLN6 in the cortex, whereas we did not observe CLN6 expression in microglia ( Figure S6C ). To quantify the number of transduced neurons, astrocytes and microglia, we counted the number of NeuN-, GFAP-and CD68-positive cells that were also positive for CLN6 staining in cortical region using the software image J. We found that in 12 months old brain sections approximately 50 percent of NeuN-, 20 percent of GFAP-and less than 5 percent of CD68-positive cells expressed CLN6 ( Figure S7 ). We also analysed the mRNA level of CLN6 across different brain regions in wild type, untreated mutant and treated mutant mice at 12 months of age. A direct comparison of the absolute number of mRNA molecules by real-time qPCR showed that the CLN6 expression levels were significantly higher in the cortex of treated mutants than the endogenous Cln6 levels in the cortex of wild type mice. No significant difference was detected between wild type and treated mutants in the visual cortex, hippocampus and thalamus ( Figure S8 ). Neuronal loss and brain atrophy is a major hallmark of CLN6 disease that is recapitulated in Cln6-deficient mice with a re- duced total brain weight and loss in cortical thickness (9, 21) . To assess the effect of gene therapy on the neurodegeneration in Cln6 nclf mice, brain sections were immunostained with an antibody against NeuN to measure cortical thickness and to enable neuronal cell counts. The S1BF region was slightly thinner in untreated Cln6 nclf mouse brains at 12 months compared with age-matched wild type controls (1889 ± 8.84 µm vs. 2075 ± 59.14 µm; p = 0.01). We did not observe a rescue of cortical thickness following treatment (1968 ± 19.10 µm). Of note, no significant further loss in thickness was detected between 12 and 22-23 months of age (1918 ± 29.81 µm) ( Figure 5A-B' ). We assessed the number of neurons by stereological counts of NeuN-positive cells in the S1BF cortical region and the VPM/VPL nuclei of the thalamus, a brain region that presents with early disease pathology in Cln6 nclf mice (9, 21) .In comparison with 12 month old wild type controls, untreated end-stage mice showed a significant loss of neurons in the S1BF region by 28% (118,980 ± 8,116 vs. 85,680 ± 2,839; p = 0.0064) and in the VPM/VPL region by 40% (37,020 ± 3,187 vs. 22,380 ± 2,613; p = 0.011). Neuronal cell counts of treated Cln6 nclf mouse brains at 12 months revealed significantly higher numbers of neurons compared with untreated brains, with a 23% increase in the S1BF region (113,700 ± 8,177; p = 0.0296) and a 30% increase in the VPM/VPL region (33,300 ± 2,076; p = 0.048). The analysis of treated Cln6 nclf mouse brains at 22-23 months showed no significant loss of neurons in the S1BF region (101,115 ± 4422; p = 0.4691) and VPM/VPL regions (29,280 ± 2196; p = 0.654) compared with 12 month-old treated mice ( Figure  5B , B", C-C'). These data demonstrate that neonatal ICV injection of AAV9.CMV.hCLN6 provide a significant and longterm amelioration of the neurodegeneration in Cln6 nclf mice.
AAV9.CMV.hCLN6 treatment prevents lysosomal pathology and the accumulation of autofluorescent storage material in mutant mice. The progressive accumulation of autofluorescent storage material in the lysosome is a major neuropathological hallmark of CLN6 disease and prominent lysosomal inclusions were reported across several brain regions in Cln6-deficient mice including S1BF, VPM/VPL and V1/V2 region (9, 21) . To assess lysosomal pathology and disease progression, we examined autofluorescence in the 488nm excitation channel and performed immunostaining against lysosomal-associated membrane protein 1 (LAMP1), a marker for late-endosomes and lysosomes. We found increased autofluorescence was consistently present close to the nucleus ( Figure 6A ) and increased LAMP1 immunostaining with larger LAMP1positive areas in the S1BF, VPM/VPL and V1/V2 regions in end-stage mutant brain sections compared with age-matched wild type controls ( Figure 6B ). The autofluorescence was reduced and LAMP1-positive accumulations appeared to be fewer and smaller in brain sections from treated mice at 12 months and 22-23 months ( Figure 6 ). To quantify LAMP1 immunostaining, thresholding immunoreactivity analysis was performed, excluding LAMP1-positive areas below 0.01 µm 2 to focus on abnormally enlarged lysosomes. Untreated end-stage mutant brain sections had significantly larger areas of LAMP1-positive immunofluorescence across all brain regions investigated compared with age-matched wild type controls (p < 0.001 for S1BF, VPM/VPL and V1/V2). Treated Cln6 nclf mice had significantly smaller areas of LAMP1-positive immunofluorescence across all regions at 12 months (p < 0.001 for S1BF, VPM/VPL and V1/V2). No significant differences were detected between sections from treated mice at 12 and 22-23 months ( Figure  6B '-B"'), highlighting the long-term therapeutic effect of the treatment. These data suggest that treatment reduces the disease-related lysosomal pathology and the accumulation of intracellular storage material in the brains of Cln6 nclf mice.
Gene therapy attenuates the microglia-and astrocytemediated immune response in Cln6 nclf mice. Finally, we assessed the effect of gene therapy on the inflammatory response by staining brain sections for CD68 and GFAP to label microglia and fibrillary astrocytes. We observed an increase in CD68-positive immunostaining in the cortex and the thalamus of untreated end-stage Cln6 nclf mouse brains compared with age-matched wild type controls and treated brains at 12 and 22-23 months of age ( Figure 7A ). In contrast with age-matched wild type controls where microglia are in a resting ramified state, activated and engorged CD68-positive microglia were present in S1BF, VPM/VPL and V1/V2 regions of untreated end-stage Cln6 nclf mice, as previously reported (9) . Treated Cln6 nclf mice showed lower levels of CD68 staining in the S1BF, VPM/VPL and V1/V2 regions at 12 and 22-23 months ( Figure 7B ). Using thresholding image analysis, CD68 staining was quantified in all three brains regions. Significantly more immunoreactivity was present in untreated brain sections than in wild type controls at 12 months (p = 0.0025 in S1BF; p = 0.0131 in VPM/VPL; p = 0.0075 in V1/V2). The brain sections from treated Cln6 nclf mice had significantly less CD68 staining at 12 months than untreated end-stage controls (p = 0.0264 in S1BF; p = 0.0313 in VPM/VPL; p = 0.0217 in V1/V2). No significant differences were detected between the immunoreactivity in treated mice that were kept for 12 and 22-23 months post vector administration. The level of the CD68 immunostaining signal was comparable in the S1BF and the V1/V2 cortical regions of treated Cln6 nclf mice at 22-23 months and wild type mice at 12 months ( Figure 7B'-B"' ). GFAP immunostaining, followed by thresholding imaging analysis demonstrated widespread astrogliosis in untreated end-stage Cln6 nclf mouse brains compared with age-matched wild type controls. Greater GFAP-positive immunostaining was consistently observed in S1BF, VPM/VPL and V1/V2 regions of untreated Cln6-deficient mice ( Figure 7C -D). Brain sections from treated Cln6 nclf mice at 12 and 22-23 months appeared to show a moderate reduction of GFAP immunostaining across all the brain regions compared with untreated end-stage mutant brain sections ( Figure 7C-D) . However, upon quantification, none of these differences reached statistical significance ( Figure 7D '-D"'). These data indicate that gene therapy had beneficial effects on the brain pathology of treated mutant mice but the treatment did not prevent an inflammatory immune response entirely.
Conclusions
Neurodegenerative LSDs such as CLN6 disease caused by mutations in genes that encode for membrane-bound proteins are more difficult targets for gene therapy than those conditions involving defective soluble enzymes. This is because the therapeutic effect from gene delivery is not further amplified through cross-correction of neighbouring cells. Recently, AAV-mediated pre-clinical gene therapy studies targeting the brain have shown efficacy in mouse models of Niemann-Pick type C1 disease (22, 23) and mucopolysaccharidosis type IIIC (MPSIIIC) (24), two neurodegenerative LSDs that are not cross-correctable. We took the approach of administering AAV9.CMV.hCLN6 via ICV injections to maximise transduction efficacy and prioritise therapeutic efficacy in the brain. We demonstrate that neonatal bilateral ICV injections of AAV9.CMV.hCLN6 with a total dose of 1x10 11 and 5x10 11 vector genomes significantly extended the survival of Cln6 nclf mice by over 90% to 23 months of age, effectively restoring normal lifespan. Furthermore, a range of behavioural tests assessing motor function of the treated mutant mice revealed either a preservation of motor skills and coordination or a complete normalisation of any deficits for almost two years following the treatment. These data demonstrate that the neonatal treatment does not only prolong the lifespan but also increases the quality of life of the treated mutant mice, an important conclusion for potential future translation into the clinic. Using landmarks of brain pathology previously established in Cln6 nclf mice by Morgan et al. (9) , we measured a reduction in neuropathological markers of the disease and a significant decrease of neuronal loss in the cerebral cortex and the thalamus following AAV gene therapy, suggesting a sustained amelioration of neurodegeneration. Lysosomal storage material and microglial-mediated inflammatory response were reduced at 12 and 22-23 months. Although an overall trend towards amelioration of astrogliosis was observed in some regions, no statistically significant decrease of the astroglial-mediated inflammatory response was detected.
Our data demonstrated neonatal brain-directed AAVmediated gene therapy successfully treats major features of CLN6 disease. However, our study also highlights some observations that require further investigation. Treated Cln6 nclf mice were more active in a short open field test as measured by an increased distance travelled and longer, more frequent visits to the centre of the test arena than age-matched wild type controls and untreated Cln6-deficient mice. It is possible that our treatment was not completely effective and uncovered a propensity for hyperactivity in Cln6-deficient mice, a phenotype that has thus far remained undetected due to a loss of mobility in the untreated animals. This may reflect increased anxiety or other neurological deficits. Assessing the open field phenotype of untreated mutants at earlier time points might have revealed disease related changes in activity behaviour of the mice at pre-symptomatic stages, which might clarify our observation. In the absence of a good antimouse Cln6 antibody, it was difficult to verify the endogenous expression pattern and level of Cln6 in the neural cell types of the mouse brain. It is possible that our treatment failed to restore sufficient levels or resulted in inappropriate expression of CLN6 for instance in astrocytes. Moreover, ICV administration of AAV9 leads to a widespread transduction of brain regions near the ventricles and the surface of the brain, but deep brain structures (e.g. the brain stem) were more sparsely transduced. It cannot be excluded that the increased activity could also be an adverse effect of a local CLN6 overexpression. However, as we did not detect any other adverse effects of vector administration in treated mutant brains it seems unlikely that the hyperactivity may be caused by the transgene overexpression. Whilst it remains unclear why treated Cln6 nclf mice showed an increased activity, these findings emphasize the importance of thorough pre-clinical animal studies prior to clinical translation.
In our study the therapeutic vector was administered to the brains of Cln6 nclf mice at an early, pre-symptomatic stage of the disease. While neonatal vector administration is relevant to families with affected children that have undergone genetic testing and received diagnosis before disease onset, the more common clinical scenario is that a therapeutic vector would be administered upon symptomatic diagnosis. Moreover, we administered a volume of 10µl of AAV at 5x10 11 and 1x10 11 vg, a total vector dose that is difficult to meet in a clinical setting. Consequently, it will be important to assess the therapeutic effects of AAV gene therapy for CLN6 disease in older, symptomatic animals, and to assess the feasibility of widespread encephalic vector administration in larger animals. Some insight into the potential future translation of our approach for NCLs can be gained from a recent preclinical gene therapy study using a sheep model of CLN5 disease with a deficiency in the soluble Cln5 protein. Bilateral ICV injections with self-complementary AAV9.CB.Cln5 in symptomatic Cln5 sheep halted disease progression. These animals lived longer than untreated sheep, yet not as long as sheep treated pre-symptomatically, indicating that gene therapy administered via ICV injections after the onset of disease symptoms can still provide meaningful benefit (25) . Importantly, our study provides the first pre-clinical data set establishing that brain-directed gene therapy rescues the behavioural and neuropathological deficits in Cln6-deficient mice. In the past, AAV-mediated gene therapies have been reported to partially correct features of the disease phenotype in a model of CLN3 disease, which similar to CLN6 disease is caused by a defective transmembrane protein. Sondhi and colleagues showed a partial restoration of the neuropathological phenotype following multiple intracranial injections of AAVrh.10.CAG.hCLN3 in neonatal Cln3 ex7-8 mice (26) . Bosch et al. demonstrated that in young adult Cln3 ex7-8 mice intravenous administration of scAAV9 carrying CLN3 under the control of a weak neuronal promoter corrected the neuropathology up to 5 months post vector administration (27) . To date, no long-term data from this study have been published. The authors also claim to rescue an early, nonprogressive rotarod phenotype. However, other studies assessing rotarod performance in Cln3 ex7-8 mice (28) and a second Cln3-deficient mouse strain (29) have not identified this phenotype. Together, these studies highlight the difficulties associated with developing brain-directed gene therapies for NCLs using models with a mild neurodegenerative phenotype. Here we have shown that a brain-directed gene therapy is therapeutic in pre-symptomatic Cln6 nclf mice, an NCL model with an earlier onset and a more severe disease progression. Our results also support ICV administration of AAV9-based gene therapy vectors as a promising strategy for other forms of NCL caused by transmembrane protein deficiencies.
Plasmid construct and recombinant AAV production.
To produce single stranded AAV9.CMV.hCLN6, the hCLN6 cDNA was cloned into a pD10 vector containing the CMV promoter as reported (19) . Briefly, recombinant AAV2/9 was produced through a triple-transient transfection method and purified by size separation on a Sephacryl S300 column followed by anion exchange chromatography using a POROS 50 HQ column as previously described (30) . Viral genome titers were determined by quantitative real-time PCR using a probe-based assay aligning to the SV40 poly-adenylation signal. Amplicon-based standard series of known amounts were used for sample interpolation. Final titres were expressed as total viral genome (vg) per pup.
Neonatal intracerebroventricular (ICV) injections.
Cln6 nclf mice were kindly provided by Prof Thomas Braulke (UKE Hamburg) and C57BL/6J mice were purchased from Harlan Laboratories (UK). Animal experiments were performed in accordance with the UK Home Office licence (PPL 70/8120) and according to ARRIVE guidelines and recommendations. At the age of post-gestational day (P) P0-P1 (under 24 hours) mouse pups received bilateral ICV injections of 5µl of vector into each lateral ventricle by using a 33-gauge needle (Hamilton, USA) as described previously (31) .Following the injections, the neonates were subsequently returned to the parent cage Animal behavioural analysis. A range of behavioural tests was conducted to assess the performance of wild type, untreated Cln6 nclf and treated Cln6 nclf mice. When automated video analysis was not possible, researchers performing quantifications were masked to each experimental cohort of mice. Accelerating rotarod: 2-month-old mice were trained on 3 consecutive days with at least 2 trials per day on an accelerating rotarod (4 rpm to 45 rpm over 5 mins, Harvard apparatus, UK). A training trial was considered successful when the mice stayed on the rod for at least 45 sec. The resting period between trials was at least 15 mins. After successful completion of the training, the mice were tested on one day per month in two trials with a resting period in between the trials. The latency to fall was measured and the trial with the better performance was used for quantification. 1-minute foot-fault test: Mice were placed on a stainlesssteel grid (35×40 cm) with a mesh size of 1.3×1.3 cm, elevated 30cm above the bench surface. The animals were let to explore the grid for 1 minute. The number of steps and the number of times a limb fell through the grid (a foot-fault mistake) was counted to calculate the percentage of incorrect steps as described previously (32) . Vertical pole climbing: Pole climbing was assessed using a 28 cm long, wooden vertical pole with a diameter of 1.4 cm. The mice were placed at the top of the pole facing downwards and were given a 1-minute window to descend the pole. At 2 months, the mice were trained on 3 consecutive days with at least 2 trials per day. A training trial was considered successful when the mice descended the pole in a coordinated manner. After successful completion of the training, every month the mice performed the test twice on one day with a resting period in between both trials. The performance was scored as follows: 1 = pass, mouse descended down the pole in a coordinated manner, 0 = fail, mouse slipped or fell down the pole. The scores were averaged for both trails per mouse and per time point. 30-seconds tail suspension test: The mice were suspended by their tails approximately 20 cm from the bench and were recorded for 30 seconds with a camera facing the abdomen of the animals as reported (33) . The clasping phenotype was scored as follows: 3 = both hind limbs extended out from the body, 2 = one hind limb is partially retracted for less than 50% of the time, 1 = both hind limbs partially retracted from more than 50% of the time, 0 = both hind limbs clearly retracted and touching the abdomen. 5 -minute open field test: To assess activity and mobility, the mice were placed in an open field arena with white walls (48×48 cm). The mice were left to explore the arena for 1 minute and subsequently the mice were recorded for 4 minutes. The automated ANY-maze software (Ireland) was used to analyse the mouse behaviour and calculate various parameters including speed (mean, average), distance, time mobile, time immobile and time spent in the centre of the arena. The arena was thoroughly cleaned with 70% ethanol in between each test.
Humane end point of study. The humane endpoint for this study was determined using a neurological welfare scoring system that assessed animal grooming, food and water intake, respiratory function, natural behaviour, provoked behaviour and neurological signs and/or a loss of 10-15% of bodyweight. Mice were not maintained for longer than 2 years of age.
Tissue collection and brain section histology. Terminal exsanguinations were performed by trans-cardiac perfusion with phosphate-buffered saline (PBS). Brains were carefully extracted and fixed in 4% paraformaldehyde (PFA) for 48h at 4°C washed with PBS and stored in 30% sucrose in PBS until cryo-protected. Brains were cryo-sectioned at a thickness of 40µm along the rostro-caudal axis at -20°C using a cryostat microtome. Immunohistochemical staining was performed to analyse transgene expression, neuropathological marker proteins and cell type specific marker proteins. Endogenous peroxidase activity was depleted by incubating sections in 1% H 2 O 2 tris-buffered saline (TBS) for 30 mins followed by three washes in TBS, after which endogenous non-specific protein binding was blocked by incubation in 15% normal serum (Sigma) in TBS-T (TBS with 0.3% Triton X-100) for 30 mins. The sections were incubated overnight in primary antibody for hCLN6 (1:500, non-commercial antiserum against CLN6 as reported (4) 
Quantitative analysis of immunohistochemical staining.
To measure the levels of immunohistochemical staining, quantitative thresholding image analysis was used as previously described (34) . For the quantification of GFAP-and CD68-postive immunostaining levels, 10 non-overlapping images were captured of each region of interest using a live video camera (Nikon, DS-Fil) mounted onto a Nikon Eclipse E600 microscope at x40 magnification with constant light intensity. For the quantification of the area occupied by LAMP1-positive accumulations, 6 to 10 non-overlapping images were captured using the same equipment and conditions as described above. Images were analysed using Image-Pro Premier (Media Cybernetics, Cambridge, UK). Immunoreactivity was measured using a constant threshold that was applied to all images for each respective antigen. Data are presented as the mean percentage area of CD68-and GFAPpositive immunoreactivity (± SD) and as the mean area of LAMP1 immunoreactive accumulations (± SD) for each region investigated. LAMP1-positive accumulations with an area below 0.01 µm 2 were discarded. To quantify the number of transduced cells also positive for NeuN, GFAP and CD68 in cortical areas manual counts were performed using the Image J software.
Stereology. Measurement of cortical thickness and quantification of neuronal cell numbers were carried out on 40µm NeuN-stained mouse brain sections using StereoInvestigator software (MBF Bioscience, Williston, VT, USA). Images were acquired on a Nikon Optiphot microscope (Nikon) attached to a Q-Imaging Model 01-MBF-2000R-CLR-12 camera (MBF Bioscience). Cortical thickness of the somatosensory barrelfield cortex (S1BF) region was obtained by calculating the average of 10 perpendicular line measurements from the pial surface to the corpus callosum white matter on every sixth sections within the S1BF. Data are presented as the average of the cortical thickness (±SEM) per animal. Neuronal cell numbers within the S1BF and VPM/VPL were estimated using the optical fractionator probe. A border was traced around the region of interest, a grid was superimposed and neurons were counted within a series of 50µm x 50µm dissector frames, which were arranged according to the sam-pling grid size. Every sixth section containing the region of interest was analysed and NeuN-positive cells were counted at 100x objective. A coefficient of error (CE) between 0.05 and 0.1 was obtained for all counts indicating sufficient sampling efficiency. Data are presented as the mean of the estimated number of neurons (±SEM) per region and animal.
Real-time qRT-PCR. Total RNA was extracted from distinct mouse brain regions using the RNeasy Mini Kit (QIAGEN). The QuantiTect Reverse Transcription Kit (QIAGEN) was utilized to generate cDNA. qRT-PCRs were performed in 96well plates in a PCR thermal cycler (Applied Biosciences 7900HT) using a 2x FastStart TagMan Probe Mastermix assay (Roche) with a probe concentration of 100 nm and a primer concentration of 200 nm with the following primers: forward b-actin (5'-AAGGCCAACCGTGAAAAGAT-3'), reverse b-actin (5'-GTGGTACGACCAGAGGCATAC-3'), forward mouse Cln6 (5'-CGGGGACTACTTTCACATGAC-3'), reverse mouse Cln6 (5'-GGGGGACCGCTCAATAAG-3'), forward human CLN6 (5'-ATCACGCCCTTTCTCTTGC-3'), reverse human CLN6 (5'-TTGACAGAGTCACCCACCAG-3'), Mouse Cln6 primers were used for wild type mouse brain samples, human CLN6 primers were used for untreated and treated mouse brain samples and b-actin primers were used for all samples as loading control. Standard curves with human and mouse CLN6 cDNA ranged from 50 pg/µl to 0.05 pg/µl. Duplicate reactions were carried out for each sample. The Ct values were calculated using the computer program SDS 2.2.2 (Applied Biosciences). The obtained Ct values were averaged per duplicate reaction, and the number of specific cDNA molecules per nanogram total mRNA was calculated by standard curve intrapolation.
Statistical analysis.
Data are presented as means ±SEM or ± SD with the indicated n-numbers representing independent animals. GraphPad Prism 5 software (USA) was used to calculate significance and the appropriate tests and p values are provided in the individual figure legends. Bibliography Fig. S1 . Overexpression of CLN6 results in mild but localised astrocyte-mediated immune response in wild type mice (A) Anti-GFAP immunostaining did not show an increase in astrogliosis in whole brain sections of wild type mice following neonatal ICV injections with AAV9.CMV.hCLN6 at 5x10 11 vg. In comparison with non-injected age-matched wild type controls, a mild up-regulation of GFAP was detected in the pre-frontal cortex when AAV9.CMV.hCLN6 was administered at 5x10 11 vg. (B) Higher magnification images confirmed a mild and confined increase in the astroglial-mediated immune response in the cortex of wild type brains following the administration of 5x10 11 vg vector. Lower titre administration did not lead to increased astrogliosis across all brain regions assessed. Scale bars (A): 1mm, (B): 100 µm.
Fig. S2. Overexpression of CLN6 did not induce microglia-mediated immune response in wild type mice.
(A-B) Anti-CD68 immunostaining did not reveal an increase in microglia activation across different brain regions following ICV administration of AAV9.CMV.hCLN6 at 5x10 10 vg or 5x10 11 vg in wild type mice compared with non-injected age-matched wild type controls. Scale bars (A): 1mm, (B): 100 µm.
Fig. S3. Quantification of the GFAP and CD68 immunoreactivity in the S1BF region of treated wild type mice.
Wild type mice that received injections with AAV9.CMV.hCLN6 at 5x10 10 vg and 5x10 11 vg did not show significantly increased GFAP (A) or CD68 immunoreactivity (B) in the S1BF region compared with untreated wild type controls. Non-injected controls, n = 3; 5x10 10 vg, n = 3; 5x10 11 vg, n = 3. Data are represented as means ± SEM, compared by one-way ANOVA.
Fig. S4. Bodyweights of wild type, untreated and treated Cln6 nclf mice over time.
Bodyweights of (A) female wild type and Cln6 nclf mice, (B) male wild type andCln6 nclf mice and (C) female and male AAV9.CMV.hCLN6treated Cln6 nclf mice over time. Female wild type, n = 4; female Cln6 nclf , n = 6; male wild type, n = 4; male Cln6 nclf , n = 7; female Cln6 nclf treated with 5x10 11 vg AAV9.CMV.hCLN6 vector, n = 1; female Cln6 nclf treated with 1x10 11 vg vector, n = 1; male Cln6 nclf treated with 5x10 11 vg vector, n = 5; male Cln6 nclf treated with 1x10 11 vg vector, n = 1. Data represented as means ± SEM. To determine the percentage of transduced neurons, astrocytes and microglia, we counted the number of NeuN-, GFAP-and CD68positive cells that were also positive for CLN6 staining in the cortical region of treated mutant brain sections using the software image J. We found that in 12 months old brain sections approximately 50 percent of NeuN-, 20 percent of GFAP-and less than 5 percent of CD68-positive cells expressed CLN6. NeuN + /CLN6 + , n = 3; GFAP + /CLN6 + , n = 3, CD68 + /CLN6 + , n = 2. Data are represented as means ± SEM.
Fig. S8. CLN6 expression levels across different brain regions of wild type, untreated mutant and treated mutant mice at 12 months of age.
A direct comparison of the absolute number of mRNA molecules by real-time qPCR showed that the CLN6 expression levels were significantly higher in the cortex of treated mutants than the endogenous Cln6 levels in the cortex of wild type mice (A). No significant difference was detected between wild type and treated mutants in the visual cortex (B), hippocampus (C) and thalamus (D). Data are represented as means ± SEM, compared by one-way ANOVA Sidak's multiple comparisons test (****p < 0.0001).
